Autoimmune sensorineural hearing loss: Clinical course and treatment outcome

Loveman, Donald M.; Comarmond, Charles de; Cepero, Ralph; Baldwin, David M.

doi:10.1016/j.semarthrit.2003.10.002

Cited by 56 publications

(38 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17] Mathews et al [18] found that ISSHL patients possessed antibody against HSP70. Loveman et al [19] detected anti-HSP70 in the serum of 27 of 30 patients (90%) with ISSHL. Although the existence of serum anti-HSP70 antibody has been investigated in most inner ear diseases, few studies have evaluated the relationship between the anti-HSP70 level and the prognosis of patients with ISSHL.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of serum anti-heat-shock protein 70 and paraoxonase levels in idiopathic sudden sensorineural hearing loss

Düzer¹

2014

Kulak Burun Bogaz Ihtis Derg

View full text Add to dashboard Cite

Objectives: This study aims to investigate the correlation between serum anti-heat-shock protein 70 (anti-HSP 70) levels, serum paraoxonase (PON) levels and prognosis of idiopathic sudden sensorineural hearing loss (ISSHL). Patients and Methods:Twenty-five patients with ISSHL as the study group and 25 healthy volunteers as the control group were enrolled in this study. Blood samples were obtained from all patients before the treatment initiation and on the 10 th day of the treatment from only patients of the study group. Idiopathic sudden sensorineural hearing loss was defined as the hearing loss between 250-6.000 Hz frequencies. The recoveries in the hearing thresholds were evaluated at 10 days of the treatment.Results: When the pre-treatment serum PON, anti-HSP 70 levels and the post-treatment serum PON, anti-HSP 70 levels of the patients with ISSHL were compared, we observed that the post-treatment serum PON levels of the recovered patients increased, while the post-treatment serum anti-HSP 70 levels of recovered patients decreased. Conclusion:We believe that serum levels of anti-HSP 70 and PON can be used as markers for estimating and evaluating the prognosis of ISSHL patients.Key Words: Heat-shock protein 70; idiopathic sudden sensorineural hearing loss; paraoxonase; prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of serum anti-heat-shock protein 70 and paraoxonase levels in idiopathic sudden sensorineural hearing loss

Düzer¹

2014

Kulak Burun Bogaz Ihtis Derg

View full text Add to dashboard Cite

show abstract

“…The fact that underlying disease is not determinable in many cases of hearing loss precludes targeting therapy to the specific cochlear processes involved and probably underlies the unpredictable, and often inconsistent, outcome of glucocorticoid treatment [7]. While convincingly beneficial to some, other studies have concluded glucocorticoids lack efficacy, and their use is still debated for some forms of hearing loss [58,59,60,61,62].…”

Section: Discussionmentioning

confidence: 99%

“…Because hearing loss is often suspected to result from immune processes [1], glucocorticoids (prednisone, prednisolone, dexamethasone) are frequently used to treat such hearing disorders as sudden or rapidly progressive hearing loss [2,3,4], Ménière’s disease [5], and autoimmune inner ear disease [6,7]. The glucocorticoids have traditionally been prescribed because of the perceived necessity for their immunosuppressive and anti-inflammatory functions in the ear.…”

Section: Introductionmentioning

confidence: 99%

Blocking the Glucocorticoid Receptor with RU-486 Does Not Prevent Glucocorticoid Control of Autoimmune Mouse Hearing Loss

Trune

Kempton²

2009

Audiol Neurotol

View full text Add to dashboard Cite

Background/Aims: Glucocorticoids effectively manage autoimmune hearing loss, although the cochlear mechanisms involved are unknown. Previous studies of steroid-responsive hearing loss in autoimmune (lupus) mice showed glucocorticoids and mineralocorticoids were equally effective, suggesting the ion homeostasis functions of glucocorticoids may be as relevant as immunosuppression for control of autoimmune-induced inner ear disease. Therefore, to better characterize the role of the glucocorticoid receptor in autoimmune hearing loss therapy, its function was blocked with the antagonist RU-486 (mifepristone) during glucocorticoid (prednisolone) treatments. Methods: Following baseline auditory brainstem response (ABR) thresholds, MRL/MpJ-Fas^lpr autoimmune mice were implanted with pellets providing combinations of 1.25 mg/kg of RU-486, 4 mg/kg of prednisolone, or their respective placebos. After 1 month, animals were retested with ABR and blood was collected for immune complex analyses. Results: Mice receiving no prednisolone (placebo + placebo and placebo + RU-486) showed continued declines in hearing. On the other hand, mice receiving prednisolone (prednisolone + placebo and prednisolone + RU-486) had significantly better hearing (p < 0.05) than the non-prednisolone groups. Immune complexes were significantly elevated in the placebo + RU-486 group, suggesting RU-486 effectively blocked glucocorticoid receptor-mediated immune suppression. These results showed that blockage of the glucocorticoid receptor with RU-486 did not prevent prednisolone’s effects in the ear, suggesting its ion homeostasis actions via the mineralocorticoid receptor were more relevant in hearing control. Conclusion: The mineralocorticoid receptor-mediated actions of glucocorticoids are potentially relevant in steroid-responsive hearing disorders, implying disrupted cochlear ion transport functions may underlie the vascular problems proposed in some forms of immune-mediated hearing loss.

show abstract

“…Autoimmune SNHL was originally defined by the presence of progressive hearing loss (with or without vertigo) and a positive response to corticosteroids [14]. Auto-immune SNHL can occur as one of the clinical features of systemic immune-mediated disorders as vasculitic syndromes, systemic lupus erythematosus, relapsing polychondritis and SSc or as a distinct clinical entity, the so-called auto-immune inner ear disease (AIED).…”

Section: Editorialmentioning

confidence: 99%

Hearing loss in systemic sclerosis - clinically important, potentially treatable and often overlooked

Gheita¹,

Fathi²

2017

ISSN 1758-4272 Int. J. Clin. Rheumatol

View full text Add to dashboard Cite

Autoimmune sensorineural hearing loss: Clinical course and treatment outcome

Cited by 56 publications

References 26 publications

Prognostic value of serum anti-heat-shock protein 70 and paraoxonase levels in idiopathic sudden sensorineural hearing loss

Prognostic value of serum anti-heat-shock protein 70 and paraoxonase levels in idiopathic sudden sensorineural hearing loss

Blocking the Glucocorticoid Receptor with RU-486 Does Not Prevent Glucocorticoid Control of Autoimmune Mouse Hearing Loss

Hearing loss in systemic sclerosis - clinically important, potentially treatable and often overlooked

Contact Info

Product

Resources

About